In a nutshell This study investigated whether the neutrophil count (NC; a type of white blood cell) and neutrophil-to-lymphocyte (another type of white blood cell) ratio (NLR) can predict prognosis in metastatic (spread to other parts of the body) melanoma patients treated with ipilimumab (Yervoy). Researchers suggested that the NC and NLR are...
Read MoreIn a nutshell This review evaluated recent evidence on the management of high-risk prostate cancer. Primary treatment options for high-risk prostate cancer were generally associated with good effectiveness, but authors advised that risk assessment is in need of refinement and standardization. Some background About 15% of men with prostate cancer...
Read More
In a nutshell ?This phase 1/2 trial aims to test the safety and effectiveness of treatment with ipilimumab (Yervoy) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in patients with stage 3 or 4 melanoma. The main outcome to be measured will be the response of the tumors to treatment. This trial is recruiting in Louisville,...
Read MoreIn a nutshell This study investigated the benefit of local therapies as first-line interventions for metastatic prostate cancer. Authors reported improved survival with radiation and surgery among men with metastatic prostate cancer at diagnosis. Some background Metastatic prostate cancer is cancer that has spread to distant parts of the body. The...
Read More
In a nutshell In this study, the American Society of Clinical Oncology Provisional Clinical Opinion (PCO) updated recommendations for treating metastatic (spread to other organs) colorectal cancer patients with RAS gene mutation. Some background RAS mutation (change) is one of the most common in colorectal tumors. This mutation can affect the...
Read More
In a nutshell This trial aimed to assess the effectiveness of using erlotinib (Tarceva) to treat EGFR-mutation positive advanced non-small-cell lung cancer. The study concluded that erlotinib had an overall survival (OS) benefit comparable to first line chemotherapy. Some background Genetic mutations (changes) in the epidermal growth factor...
Read More
In a nutshell This study investigated the association between palliative surgery (a treatment that reduces pain without curing the disease) and quality of life in colorectal patients with incurable metastasis (cancer has spread to other parts of the body). Researchers reported that surgery led to an improved quality of life in these...
Read More
In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC. Some background Hormone therapy is the standard of care for advanced prostate cancer, including...
Read More
In a nutshell This study investigated the safety and effectiveness of the drug eribulin (Halaven) for the treatment of patients with metastatic breast cancer and resistance to taxane therapies. The study concluded that eribulin was effective and well tolerated in patients with metastatic breast cancer. Some background Taxanes are a type of...
Read More
In a nutshell This study investigated the association between the tumor side and cetuximab (Erbitux) effectiveness in metastatic (spread to other parts of the body) colorectal cancer. Researchers reported that cetuximab was more effective in left-sided tumors. Some background Left and right- sided colorectal cancer have different...
Read More
In a nutshell This study examined the predictive value of circulating tumor cells (CTCs) during docetaxel (Taxotere) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers reported a strong association between CTCs and treatment response to docetaxel. Some background Hormone therapy is the standard of care for advanced...
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
